Development of Clinical Methods of Iron Deprivation for Suppression of Neoplastic and Infectious Diseases

References

• Moirand R, Mortaji A M, Loreal O. A new syndrome of liver iron overload with normal transfenin saturation. Lancet 1997; 349: 95–97
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G J, Weinberg E D. Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 1995; 9: 33–45
   PubMed Web of Science ®Google Scholar
• Porter J B, Huehns E R, Hider R C. The development of iron chelating drugs. Baillier's Clin Haematol 1989; 2: 257–292
   PubMedGoogle Scholar
• Weinberg E D. The role of iron in cancer. Eur J Cancer Prevent 1996; 5: 19–36
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Brittenham G M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739–761
   PubMed Web of Science ®Google Scholar
• Hann H-WL, Stahlhut M W, Rubin R. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992; 70: 2051–2056
   PubMed Web of Science ®Google Scholar
• Donfrancesco A, Deb G, De Sio L. Role of deferoxamine in tumor therapy. Acta Haematol 1996; 95: 66–69
   PubMed Web of Science ®Google Scholar
• Boelaert J R, De Locht M, Van Cutsem J. Desfenioxamine: its effects on the growth of micro-organisms in vitro and in experimental infections. Rev Med Microbiol 1993; 4: 171–175
   Google Scholar
• Hider R C, Liu Z. The treatment of malaria with iron chelators. J Phann Pharmacol 1997; 49: 59–64, Suppl 2
   Web of Science ®Google Scholar
• Weinberg G A. lron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 1994; 38: 997–1003
   PubMed Web of Science ®Google Scholar
• Weinberg E D. Iron withholding: a defense against viral infections. Bio Metals 1996; 9: 393–399
   Google Scholar
• Brittenham G M. Development of iron-chelating agents for clinical use. Blood 1992; 80: 569–574
   PubMed Web of Science ®Google Scholar
• Timeus F, Valle P, Crescenzio N. Effect of desfemoxamine and hydroxypyridones on hemopoietic progenitors and neuro-ectodennal tumor cells. Am J Hematol 1994; 47: 183–188
   PubMedGoogle Scholar
• Richardson D R, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-l-naphthyl-aldehyde benzoyl hydrazone. Blood 1997; 89: 3025–3038
   PubMed Web of Science ®Google Scholar
• Dabrowiak J C. The coordination chemistry of bleomycin: a review. J Inorg Biochem 1980; 13: 317–337
   Web of Science ®Google Scholar
• Myers C, Gianni L, Zweier J. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. Federation Proc 1986; 45: 2792–2797
   PubMedGoogle Scholar
• Moore J C, Lai H, Li J-R. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 1995; 98: 83–87
   PubMed Web of Science ®Google Scholar
• Meshnick S R, Taylor T E, Kamchonwomgpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60: 301–315
   PubMedGoogle Scholar
• Byrd T F, Horwitz M A. Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human monocytes depending upon its degree of iron saturation. J Clin Invest 1991; 88: 1103–1112
   PubMed Web of Science ®Google Scholar
• Bezault J, Bhimani R, Wiprovnik J. Human lactoferrin inhibits growth of solid tumors and development of metastases in mice. Cancer Res 1994; 54: 2310–2312
   PubMed Web of Science ®Google Scholar
• Dhaenens L, Szczebara F, Husson M O. Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect Immun 1997; 65: 514–518
   PubMed Web of Science ®Google Scholar
• Miehlke S, Reddy R, Osato M S. Direct activity of recombinant human lactofemn against Helicobacter pylori. J Clin Microbiol 1996; 34: 2593–2594
   PubMed Web of Science ®Google Scholar
• Oguchi S, Walker W A, Sanderson I R. Iron saturation alters the effect of lactofemn on the proliferation and differentiation of human enterocytes (Caco-2 cells). Biol Neonate 1995; 67: 330–339
   PubMedGoogle Scholar
• Brock J H, Djeha A, Ismail M. Cellular responses to iron and iron compounds. Progress in Iron Research, C Hershko. Plenum Press, New York 1994; 91–100
   Google Scholar
• Witte D L, Crosby W H, Edwards C Q. Hereditary hemochro-matosis. Clin Chim Acta 1996; 245: 139–200
   PubMed Web of Science ®Google Scholar
• Merk K, Mattson B, Mattson A. The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: 505–509
   PubMed Web of Science ®Google Scholar
• Weinberg R J, Ell S R, Weinberg E D. Blood-letting, iron homeostasis, and human health. Med Hypoth 1986; 21: 441–443
   PubMed Web of Science ®Google Scholar
• Rush B. A defense of blood letting as a remedy for certain diseases. Medical Inquiries & Observations, Vol. IV, M Carey, Philadelphia 1818; 173–224
   Google Scholar
• Israel J L, McGlynn K A, Hann H-WL, Blumberg B S. Iron-related markers in liver cancer. Iron in Immunity, Cancer and Inflammation, M DeSousa, JH Brock. John Wiley, Chichester 1989; 301–316
   Google Scholar
• Rubin R B, Barton A L, Banner B F. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 1995; 13: 223–238
   PubMed Web of Science ®Google Scholar
• Ikura Y, Morimoto H, Johmura H. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis c. Am J Gastroenterol 1996; 91: 1367–1373
   PubMed Web of Science ®Google Scholar
• Bacon B R, Rebholz A E, Fried M. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-α. Hepatology 1993; 18: 150A
   Web of Science ®Google Scholar
• Hayashi I, Takikawa T, Nishimura N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepa. titis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986–988
   PubMed Web of Science ®Google Scholar
• Pipemo A, Sampietro M, D'Alba R. Iron stores, response to α-interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248–254
   PubMedGoogle Scholar
• Van Thiel D H, Friedlander L, Molloy P J. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996; 43: 1557–1561
   PubMed Web of Science ®Google Scholar
• Meyer B, Muller F, Luus H. Faecal blood loss associated with aspirin and pentoxifylline, given alone and in combination. Drug Invest 1992; 4: 215–218
   Google Scholar
• Thun M J, Namboodiri M M, Heath CW, Jr. Aspirin use and reduced risk of colon cancer. N Engl J Med 1991; 325: 1593–1596
   PubMed Web of Science ®Google Scholar
• Weinberg E D. Iron depletion: a defense against intracellular infection and neoplasia. Life Sci 1992; 50: 1289–1297
   PubMed Web of Science ®Google Scholar
• James S L. Role of nitric oxide in parasitic infections. Microbiol Rev 1995; 59: 533–547
   PubMedGoogle Scholar
• Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. Parent Enter Nutr 1986; 10: 227–238
   PubMed Web of Science ®Google Scholar
• Vincendeau P, Daulouede S, Veyret B. Nitric oxidemediated cytostatic activity on Trypanosoma brucei gambiense and Try-panosoma brucei brucei. Exp Parasitol 1992; 75: 353–360
   PubMed Web of Science ®Google Scholar
• Karupiah G, Harris N. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J Exp Med 1995; 181: 2171–2179
   PubMed Web of Science ®Google Scholar
• Clark I A, Rockett M A. Nitric oxide and parasitic disease. Adv Parasitol 1996; 37: 5–36
   Google Scholar
• Weinberg E D. Acquisition of iron and other nutrients in vivo. Virulence Mechanisms of Bacterial Pathogens, J A Roth, CA Bolin, KA Brogdon. Am Soc Microbiol, Washington, DC 1995; 79–94
   Google Scholar
• Ala'aldeeri DAA, Stevenson P, Griffiths E. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect Immun 1994; 62: 2984–2990
   PubMed Web of Science ®Google Scholar
• Holland J, Parsons T R, Hasan A A. Conservation and antigenic sross-reactivity of the transferrin-binding proteins of Haemophilus influenzae, Actinobacillus pleuropneumoniae and Neisseria meningitidis. Microbiology 1996; 142: 3505–3513
   PubMed Web of Science ®Google Scholar
• Worst D J, Spanius M, Kuipers E J. Human serum antibody response against iron-repressible outer membrane proteins of Helicobacter pylori. FEMS Microbiol Lett 1996; 144: 29–32
   PubMed Web of Science ®Google Scholar
• Lundberg J H, Chitambar C R. Interaction of gallium nitrate with fluarabine and iron chelators: effects on the proliferation of human leukaemic HL60 cells. Cancer Res 1990; 50: 6466–6470
   PubMed Web of Science ®Google Scholar
• Kemp J D, Smith K M, Mayer J M. Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells. Pathobiology 1992; 60: 27–32
   PubMed Web of Science ®Google Scholar
• Taetle R, Honeysett J M, Bergeron R. Combination iron depletion therapy. J Natl Cancer Inst 1989; 81: 1229–1235
   PubMed Web of Science ®Google Scholar
• Kemp J D. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol Histopathol 1997; 12: 291–296
   PubMed Web of Science ®Google Scholar
• Hsieh-Ma S, Shi T, Reeder J. In vitro tumor growth inhibition by bispecific antibodies to human transfenin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin Immunol Immunopathol 1996; 80: 185–193
   PubMedGoogle Scholar
• Chitambar C R, Narasimhan J. Targetting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 1991; 59: 3–10
   PubMed Web of Science ®Google Scholar
• Chitambar C R, Boon P, Wereley J. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin Cancer Res 1996; 2: 1009–1015
   PubMed Web of Science ®Google Scholar
• Seligman P A, Schleicher R B, Siriwardana G. Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood 1993; 82: 1608–1617
   PubMed Web of Science ®Google Scholar
• Dreicer R, Propert K J, Roth B J. Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium. Cancer 1997; 79: 110–114
   PubMed Web of Science ®Google Scholar
• Byrd T F, Honvitz M A. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 1991; 88: 351–357
   PubMed Web of Science ®Google Scholar
• Newman S L, Gootee L, Brunner G. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest 1994; 93: 1422–1429
   PubMed Web of Science ®Google Scholar
• Tsai W-P, Nara P L, Kung H-F. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990; 6: 481–489
   PubMed Web of Science ®Google Scholar
• Sperber K, Kalb T H, Stecher V J. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993; 9: 91–98
   PubMed Web of Science ®Google Scholar
• Sperber K, Louis M, Kraus T. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17: 622–625
   PubMed Web of Science ®Google Scholar